Growth hormone response to the GABA(B) agonist baclofen in major depressive disorder

Lori L. Davis, Madhukar Trivedi, Amy Choate, Gerald L. Kramer, Frederick Petty

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Growth hormone (GH) response to the γ-aminobutyric acid B receptor agonist, baclofen, was measured in 16 male patients with major depressive disorder and in 16 age-matched healthy male controls. No significant differences were found in the GH response to baclofen between the depressed patients and controls. On repeat testing, the GH response to baclofen showed significant retest reliability in both groups. There was no significant correlation between serum baclofen levels and the GH response to baclofen. Age significantly correlated with GH response, with older subjects having lower GH response to baclofen. These data do not suggest that a blunted GH response to baclofen represents a specific neuroendocrine feature of major depression.

Original languageEnglish (US)
Pages (from-to)129-140
Number of pages12
Issue number3
StatePublished - Apr 1997


  • Baclofen
  • GABA-B receptor
  • Growth hormone
  • Major depression
  • Neuroendocrine
  • γ-aminobutyric acid

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Growth hormone response to the GABA(B) agonist baclofen in major depressive disorder'. Together they form a unique fingerprint.

Cite this